CRANBURY, N.J., April 10, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) announced today the pricing of an underwritten public offering of 10,340,000 shares of its common stock, 15-month warrants to purchase up to an aggregate of 10,340,000 shares of common stock, and 5-year warrants to purchase up to an aggregate of 10,340,000 shares of common stock. BioLexis Pte. Ltd., the Company’s strategic business partner and largest stockholder, led this financing with a $10 million investment.

About Outlook Therapeutics

Outlook Therapeutics is a clinical-stage biopharmaceutical company focused on developing its complex, technically challenging and commercially attractive monoclonal antibody product candidate, ONS 5010, for various ophthalmic indications. ONS-5010 is currently in Phase 3 clinical trials for patients suffering from wet age-related macular degeneration.